Precision Medicine in the Management of Heart Transplant Recipients

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Jan 9, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on improving the care of heart transplant patients by using a special approach that combines different types of medical information, including blood tests, imaging scans, and machine learning technology. The goal is to identify patients who might be at a higher risk for issues like organ rejection or infections, which can affect their health after the transplant. By better understanding these risks, doctors hope to provide more personalized care that can lead to better outcomes for patients.

To be eligible for this trial, participants need to be at least 18 years old and have received a heart transplant. They should also need a heart tissue biopsy, which is a test doctors use to check for signs of rejection or other problems. Patients in the study will continue to receive their usual medical care, and the results from any tests done for the study will not change how their doctors treat them. If you're considering joining this trial, it could be a valuable opportunity to contribute to important research while receiving standard care for your heart health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Have received an orthotopic heart transplant
• • Clinical indication for performing a myocardial biopsy (either as part of standard monitoring or for suspected rejection)
• • Obtaining informed consent
• Exclusion Criteria:
• • Severe complications in the post-operative phase that may limit the patient's short-term survival.